All In Biotech

Drug Trial Radar · NCT01856920

QUILT-3.006 for Recurrent Medullary Thyroid Cancer

A Phase 2 Study of GI-6207 in Patients With Recurrent Medullary Thyroid Cancer

Last checked: Nov 20, 2026Latest source record: Jul 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

35

Actual

Start

Mar 26, 2013

Primary completion

May 8, 2018

Study completion May 8, 2018

Sponsor

Lead sponsor
NantCell, Inc.Industry
Sponsor type
Industry
Collaborators
National Cancer Institute (NCI)
First posted
May 20, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Background: \- GI-6207 is an experimental cancer vaccine made with baker's yeast. The yeast has been modified to help the immune system target a protein called CEA. CEA is found on the surface of some kinds of tumor cells, including thyroid cancer cells. Researchers want to see if GI-6207 can encourage the body's immune system to attack and kill tumor cells that contain the CEA protein. They will test to see whether this vaccine is a safe and effective treatment for medullary thyroid cancer that has not responded to earlier treatments. Objectives: \- To test the safety and effectiveness of the GI-6207 vaccine for advanced medullary thyroid cancer. Eligibility: \- Individuals at least 18 years of age who have medullary thyroid cancer that has not responded to earlier treatments. Design: * Participants will be screened with a physical exam and medical history. They will provide blood and tumor samples and have an imaging study of the neck and chest. They will also have a skin test to make sure that they are not allergic to the yeast in the vaccine. * Participants will be divided into two groups. One group will start to take GI-6207 immediately for 1 year. The second group will have 6 months of monitoring and tests with no vaccine, and then will take GI-6207 for 1 year. * GI-6207 will be given every other week for the first seven visits (about 3 months), and then monthly for the remaining year of treatment. It will be given as injections beneath the arm and in the upper thigh. These locations will help the vaccine enter the lymph nodes and reach the immune system more quickly. * Participants will be monitored with frequent blood and urine tests and imaging studies. * Participants will have regular follow-up visits after their year of study vaccines.

Conditions

  • Medullary Thyroid Cancer (MTC)

Interventions

  • GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]Biological

    GI-6207 is a heat-killed, recombinant yeast-based vaccine engineered to express the full length human carcinoembryonic antigen (CEA), with a modified gene coding sequence to code for a single amino acid substitution (asparagine to aspartic acid) at the native protein amino acid position 610, which is designed to enhance immunogenicity. A plasmid vector containing the modified human CEA gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wild-type yeast) to produce the final recombinant vaccine product.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Calcitonin Growth RateTime frame: after 6 months of therapy

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • NIH Clinical Center

    Bethesda, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.